INCANNEX HEALTHCARE INC (IXHL) Fundamental Analysis & Valuation

NASDAQ:IXHL • US45333F2083

Current stock price

3.65 USD
+0.1 (+2.82%)
Last:

This IXHL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IXHL Profitability Analysis

1.1 Basic Checks

  • In the past year IXHL has reported negative net income.
  • IXHL had a negative operating cash flow in the past year.
  • IXHL had negative earnings in each of the past 5 years.
  • IXHL had a negative operating cash flow in each of the past 5 years.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of IXHL (-64.66%) is worse than 72.77% of its industry peers.
  • Looking at the Return On Equity, with a value of -66.07%, IXHL is in line with its industry, outperforming 43.98% of the companies in the same industry.
Industry RankSector Rank
ROA -64.66%
ROE -66.07%
ROIC N/A
ROA(3y)-180.94%
ROA(5y)-141.08%
ROE(3y)-249.71%
ROE(5y)-184.94%
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

1.3 Margins

  • IXHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IXHL Health Analysis

2.1 Basic Checks

  • IXHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IXHL has been increased compared to 1 year ago.
  • IXHL has less shares outstanding than it did 5 years ago.
  • IXHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • An Altman-Z score of 15.43 indicates that IXHL is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 15.43, IXHL belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
  • IXHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.43
ROIC/WACCN/A
WACC9.8%
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 48.27 indicates that IXHL has no problem at all paying its short term obligations.
  • IXHL has a better Current ratio (48.27) than 98.95% of its industry peers.
  • IXHL has a Quick Ratio of 48.27. This indicates that IXHL is financially healthy and has no problem in meeting its short term obligations.
  • IXHL's Quick ratio of 48.27 is amongst the best of the industry. IXHL outperforms 98.95% of its industry peers.
Industry RankSector Rank
Current Ratio 48.27
Quick Ratio 48.27
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IXHL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.63% over the past year.
  • The Revenue for IXHL has decreased by -100.00% in the past year. This is quite bad
  • IXHL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -31.02% yearly.
EPS 1Y (TTM)55.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-46.82%
Revenue growth 5Y-31.02%
Sales Q2Q%-100%

3.2 Future

  • IXHL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.47% yearly.
  • Based on estimates for the next years, IXHL will show a very strong growth in Revenue. The Revenue will grow by 1900.01% on average per year.
EPS Next Y99.78%
EPS Next 2Y41.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2027 20M 40M 60M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

4

4. IXHL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IXHL. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 2.82, the valuation of IXHL can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IXHL indicates a rather cheap valuation: IXHL is cheaper than 97.38% of the companies listed in the same industry.
  • IXHL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.96.
Industry RankSector Rank
PE N/A
Fwd PE 2.82
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

  • IXHL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • IXHL's earnings are expected to grow with 41.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IXHL Dividend Analysis

5.1 Amount

  • No dividends for IXHL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IXHL Fundamentals: All Metrics, Ratios and Statistics

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (4/14/2026, 1:28:21 PM)

3.65

+0.1 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13
Earnings (Next)05-13
Inst Owners2.89%
Inst Owner Change149.46%
Ins Owners10.56%
Ins Owner Change91.78%
Market Cap50.99M
Revenue(TTM)N/A
Net Income(TTM)-48.50M
AnalystsN/A
Price TargetN/A
Short Float %6.52%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.5%
Min EPS beat(2)36.5%
Max EPS beat(2)36.5%
EPS beat(4)3
Avg EPS beat(4)-205.68%
Min EPS beat(4)-978.6%
Max EPS beat(4)82.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-2900%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.82
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)-255.48
EYN/A
EPS(NY)1.3
Fwd EY35.5%
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0
BVpS5.25
TBVpS5.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.66%
ROE -66.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-180.94%
ROA(5y)-141.08%
ROE(3y)-249.71%
ROE(5y)-184.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 48.27
Quick Ratio 48.27
Altman-Z 15.43
F-Score4
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
EPS Next Y99.78%
EPS Next 2Y41.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-46.82%
Revenue growth 5Y-31.02%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-35.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.24%
OCF growth 3YN/A
OCF growth 5YN/A

INCANNEX HEALTHCARE INC / IXHL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INCANNEX HEALTHCARE INC (IXHL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IXHL.


What is the valuation status of INCANNEX HEALTHCARE INC (IXHL) stock?

ChartMill assigns a valuation rating of 4 / 10 to INCANNEX HEALTHCARE INC (IXHL). This can be considered as Fairly Valued.


Can you provide the profitability details for INCANNEX HEALTHCARE INC?

INCANNEX HEALTHCARE INC (IXHL) has a profitability rating of 0 / 10.


How financially healthy is INCANNEX HEALTHCARE INC?

The financial health rating of INCANNEX HEALTHCARE INC (IXHL) is 9 / 10.